Refined By:
Author:  Mikov, Momir

Results 1-20 of 24 (Search time: 0.004 seconds).

Issue DateTitleAuthor(s)
1201812-oxo chenodeoxycholic acid potentiates doxorubicin-induced oxidative stress through Nrf2 axis in breast adenocarcinoma cellsBojan Stanimirov ; Karmen Stankov ; Nebojša Pavlović ; Maja Đanić ; Jasmina Katanić ; Iva Barjaktarović ; Momir Mikov 
22017Antioxidant effects of ursodeoxycholic acid in doxorubicin-induced oxidative hepatocyte injuryBojan Stanimirov ; Karmen Stankov ; Nebojša Pavlović ; Maja Đanić ; Svetlana Goločorbin-Kon ; Velibor Vasović ; Momir Mikov 
31-Aug-2013The bile acid membrane receptor TGR5: A novel pharmacological target in metabolic, inflammatory and neoplastic disordersVanesa Stepanov ; Karmen Stankov ; Momir Mikov 
42018Bile acid potentiates apoptosis of human breast adenocarcinoma cells induced by doxorubicinBojan Stanimirov ; Karmen Stankov ; Nebojša Pavlović ; Maja Đanić ; Bogdanović G; Vesna Kojić ; Momir Mikov 
51-Feb-2015Bile acid signaling through farnesoid X and TGR5 receptors in hepatobiliary and intestinal diseasesStanimirov, Bojan ; Stankov, Karmen ; Mikov, Momir 
68-Nov-2018Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profilesNebojša Pavlović ; Svetlana Goločorbin-Kon ; Maja Đanić ; Bojan Stanimirov ; Hani Al-Salami; Karmen Stankov ; Momir Mikov 
71-Jan-2014C-KIT signaling in cancer treatmentStankov, Karmen ; Popović, Živko; Mikov, Momir 
8Feb-2020DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal ImpairmentMomir Mikov ; Nebojša Pavlović ; Bojan Stanimirov ; Maja Đanić ; Svetlana Goločorbin-Kon ; Karmen Stankov ; Hani Al-Salami
91-Jan-2019DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal ImpairmentMikov, Momir ; Pavlović, Nebojša ; Stanimirov, Bojan ; Đanić, Maja ; Goločorbin-Kon, Svetlana ; Stankov, Karmen ; Al-Salami H.
101-Jan-2012Effect of simultaneous exposure to benzene and ethanol on urinary thioether excretionIvan Mikov ; Karmen Stankov ; Velibor Vasović ; Aleksandra Mikov ; Svetlana Goločorbin-Kon ; Momir Mikov 
112016The effects of usodeoxycholic acid on cytotoxic activity and proapoptotic potential of doxorubicin in MCF-7 cell lineBojan Stanimirov ; Karmen Stankov ; Nebojša Pavlović ; Maja Đanić ; Vesna Kojić ; Iva Barjaktarović ; Momir Mikov 
121-Apr-2012Ethical and legal aspects of oncogenomicsStankov, Karmen ; Drašković, Dragan ; Mikov, Momir 
131-Jan-2012The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel diseaseStojancevic M.; Stankov, Karmen ; Mikov, Momir 
142019In silico alternatives to animal testing: state of the artNebojša Pavlović ; Svetlana Goločorbin-Kon ; Karmen Stankov ; Maja Đanić ; Bojan Stanimirov ; Mladena Lalić-Popović ; Momir Mikov 
151-Jan-2019In silico discovery of resveratrol analogues as potential agents in treatment of metabolic disordersNebojša Pavlović ; Maja Đanić ; Bojan Stanimirov ; Svetlana Goločorbin-Kon ; Karmen Stankov ; Mladena Lalić-Popović ; Momir Mikov 
162018In vivo effects of ursodeoxycholic acid on doxorubicin-induced oxidative injury of hepatocyteBojan Stanimirov ; Karmen Stankov ; Nebojša Pavlović ; Maja Đanić ; Svetlana Goločorbin-Kon ; Momir Mikov 
172018Non-toxic bile acids as pharmaceutical excipients may alter pharmacological activity of antitumor drug vorinostatNebojša Pavlović ; Karmen Stankov ; Svetlana Goločorbin-Kon ; Mladena Lalić-Popović ; Bojan Stanimirov ; Maja Đanić ; Momir Mikov 
181-Feb-2013Pharmacogenetic biomarkers as tools for pharmacoepidemiology of severe adverse drug reactionsStankov, Karmen ; Sabo, Ana ; Mikov, Momir 
191-Jan-2018Pharmacological applications of bile acids and their derivatives in the treatment of metabolic syndromeMaja Đanić ; Bojan Stanimirov ; Nebojša Pavlović ; Svetlana Goločorbin-Kon ; Hani Al-Salami; Karmen Stankov ; Momir Mikov 
201-Dec-2012Pleiotropic functions of bile acids mediated by the farnesoid X receptorStanimirov, Bojan ; Stankov, Karmen ; Mikov, Momir